How many clinical-trial readouts are scheduled for March 2027?

pdufa.bio currently tracks 45 clinical-trial readouts with dates in March 2027, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Decisions Readouts Run-up Stocks

Drug Index Conferences Advisory Committees Screener Research API SLS tracker Account

Pro

Home › Readouts › March 2027

March 2027 clinical-trial readouts

Updated August 7, 2026·next FDA decision on the calendar

trial-readout estimates for March 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← February 2027 April 2027 →

14 readouts

MNKD · Mar 2027 (est.)

Afrezza: Type 1 Diabetes Mellitus

NUVB · Mar 2027 (est.)

safusidenib: Advanced Solid Tumor

Awaiting dataupdated 5mo ago

OCGN · Mar 2027 (est.)

OCU410ST: Retinitis Pigmentosa

Awaiting dataupdated 11mo ago

ONC · Mar 2027 (est.)

Zanubrutinib: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

PCVX · Mar 2027 (est.)

31-valent pneumococcal conjugate vaccine: Pneumococcal Vaccines

Awaiting data

AGIO · Mar 2027 (est.)

Mitapivat: Chondrosarcoma

Awaiting data

IPHA · Mar 2027 (est.)

Monalizumab: Metastatic Cancer

Awaiting data

MDGL · Mar 2027 (est.)

Resmetirom: Non-Alcoholic Fatty Liver Disease

Awaiting data

IONS · Mar 2027 (est.)

Olezarsen: Severe Hypertriglyceridemia

COGT · Mar 2027 (est.)

CGT9486: Intrahepatic Cholangiocarcinoma (Icc)

DNLI · Mar 2027 (est.)

BIIB122: Parkinson Disease

Awaiting data

TSHA · Mar 2027 (est.)

TSHA-101: Infantile GM2 Gangliosidosis (Disorder)

Awaiting dataupdated 38mo ago

GILD · Mar 2027 (est.)

Sacituzumab Govitecan: HER2-negative Breast Cancer

CLDX · Mar 2027 (est.)

Barzolvolimab: Glioblastoma

Awaiting data

Looking for an approval probability for these? We deliberately don't publish one. Here's why, and what we show instead (verified history + base rates).